D&D Pharmatech Statistics

Total Valuation

D&D Pharmatech has a market cap or net worth of KRW 1.42 trillion. The enterprise value is 1.40 trillion.

Market Cap	1.42T
Enterprise Value	1.40T

Important Dates

The next estimated earnings date is Tuesday, August 12, 2025.

Earnings Date	Aug 12, 2025
Ex-Dividend Date	n/a

Share Statistics

D&D Pharmatech has 10.75 million shares outstanding. The number of shares has increased by 14.93% in one year.

Current Share Class	10.75M
Shares Outstanding	10.75M
Shares Change (YoY)	+14.93%
Shares Change (QoQ)	+0.53%
Owned by Insiders (%)	20.68%
Owned by Institutions (%)	7.45%
Float	8.05M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	132.29
PB Ratio	22.51
P/TBV Ratio	46.90
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-42.56
EV / Sales	130.58
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-54.58

Financial Position

The company has a current ratio of 3.54, with a Debt / Equity ratio of 0.14.

Current Ratio	3.54
Quick Ratio	3.16
Debt / Equity	0.14
Debt / EBITDA	n/a
Debt / FCF	-0.33
Interest Coverage	-46.75

Financial Efficiency

Return on equity (ROE) is -57.28% and return on invested capital (ROIC) is -26.90%.

Return on Equity (ROE)	-57.28%
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	-26.90%
Return on Capital Employed (ROCE)	-36.70%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	-463.85M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +377.43% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+377.43%
50-Day Moving Average	89,378.00
200-Day Moving Average	57,178.75
Relative Strength Index (RSI)	61.69
Average Volume (20 Days)	436,678

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, D&D Pharmatech had revenue of KRW 10.75 billion and -32.98 billion in losses. Loss per share was -3,151.24.

Revenue	10.75B
Gross Profit	10.73B
Operating Income	-29.07B
Pretax Income	-34.37B
Net Income	-32.98B
EBITDA	-23.53B
EBIT	-29.07B
Loss Per Share	-3,151.24

Full Income Statement

Balance Sheet

The company has 26.15 billion in cash and 8.54 billion in debt, giving a net cash position of 17.61 billion or 1,638.64 per share.

Cash & Cash Equivalents	26.15B
Total Debt	8.54B
Net Cash	17.61B
Net Cash Per Share	1,638.64
Equity (Book Value)	63.18B
Book Value Per Share	5,970.15
Working Capital	23.73B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -25.32 billion and capital expenditures -397.18 million, giving a free cash flow of -25.72 billion.

Operating Cash Flow	-25.32B
Capital Expenditures	-397.18M
Free Cash Flow	-25.72B
FCF Per Share	-2,392.74

Full Cash Flow Statement

Margins

Gross Margin	99.79%
Operating Margin	-270.44%
Pretax Margin	-319.80%
Profit Margin	n/a
EBITDA Margin	-218.97%
EBIT Margin	-270.44%
FCF Margin	n/a

Dividends & Yields

D&D Pharmatech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-14.93%
Shareholder Yield	n/a
Earnings Yield	-2.32%
FCF Yield	-1.81%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

D&D Pharmatech has an Altman Z-Score of 4.58 and a Piotroski F-Score of 1.

Altman Z-Score	4.58
Piotroski F-Score	1